NCT06745492

Brief Summary

This study is a prospective observational study. A total of 54 patients were included in this study. We observed the time from neostigmine administration to TOF ratio of 1.0.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
59

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Oct 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2022

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 20, 2023

Completed
5 days until next milestone

Study Completion

Last participant's last visit for all outcomes

August 25, 2023

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

December 17, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

December 20, 2024

Completed
Last Updated

December 20, 2024

Status Verified

December 1, 2024

Enrollment Period

11 months

First QC Date

December 17, 2024

Last Update Submit

December 17, 2024

Conditions

Recovery Time

Outcome Measures

Primary Outcomes (1)

  • Recovery time

    Time from neostigmine administration to TOF ratio of 1.0

    During surgery

Interventions

Neostigmine + GlycopyrrolateDRUG

a 20 mcg/kg of neostigmine and 4 mcg/kg of glycopyrrolate were administered at a TOF ratio of 0.7.

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients undergoing elective thyroid surgery under general anesthesia were screened and included in this study

You may qualify if:

  • Patients undergoing elective thyroid surgery under general anesthesia
  • a body mass index of 18.5-25 kg/m2
  • Age ≥ 20

You may not qualify if:

  • Refused to participate
  • history of hypersensitivity to acetylcholinesterase inhibitor
  • neuromuscular disease
  • hepatic or renal dysfunction

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Bundang Hospital

Seongnam, South Korea

Location

MeSH Terms

Interventions

NeostigmineGlycopyrrolate

Intervention Hierarchy (Ancestors)

Phenylammonium CompoundsQuaternary Ammonium CompoundsAminesOrganic ChemicalsOnium CompoundsPyrrolidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Chang-Hoon Koo

    Seoul National University Bundang Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

December 17, 2024

First Posted

December 20, 2024

Study Start

October 1, 2022

Primary Completion

August 20, 2023

Study Completion

August 25, 2023

Last Updated

December 20, 2024

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will not share

Locations

KR(1)